Christine Barlaam

Title: **Innovative Contributions of Christine Barlaam in Pain Treatment**

Introduction

Christine Barlaam, an inventive researcher based in Reims, France, has made significant strides in the field of pharmaceuticals. With a total of three patents to her name, she has focused her efforts on developing compounds to treat pain effectively.

Latest Patents

Her most recent patents include innovative compounds such as 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones. These compounds have demonstrated potential use for pain treatment, underlining the importance of her research. Notably, an examiner's statement highlighted that the amendments made to her claims restricted the variable 'E' to phenyl or cycloalkyl groups, thus resolving previous objections which suggested that 'E' only pertained to alkyl. Another patent describes the compound 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, including its enantiomers and pharmaceutically-acceptable salts for administering pain relief.

Career Highlights

Christine's work at AstraZeneca AB has positioned her at the forefront of pharmaceutical innovation. Her contributions extend beyond mere patent filings; they represent pivotal advancements in treating pain using novel chemical entities. Her commitment to research and development is evidenced by her successful patent applications and the applications of her discoveries in real-world medical scenarios.

Collaborations

Throughout her career, Christine has collaborated with esteemed colleagues, including Dean Brown and Rebecca Urbanek. These partnerships have fostered an environment of creativity and innovation, allowing for the sharing of ideas and expertise that enhance the scientific community's understanding of pain management.

Conclusion

Christine Barlaam exemplifies dedication and ingenuity in her field. Her work not only contributes to scientific knowledge but also has the potential to significantly impact patient care and treatment options for pain. With her patents and collaborative efforts, she continues to inspire future innovations in pharmaceutical research.